Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jan;31(1):25-32.
doi: 10.18553/jmcp.2025.31.1.25.

Estimating optimal thresholds for adherence to RASA medications among older adults with hypertension

Megha A Parikh  1 , Sujith Ramachandran  2 , Irene Nsiah  2 , Patrick J Campbell  3 , Melissa Castora-Binkley  1 , Taruja Karmakar  3 , Heather Black  3 , John P Bentley  2
Affiliations

Estimating optimal thresholds for adherence to RASA medications among older adults with hypertension

Megha A Parikh et al. J Manag Care Spec Pharm. 2025 Jan.

Abstract

Background: The Centers for Medicare and Medicaid Services (CMS) Star Ratings program incentivizes health plans in Medicare to improve performance on a variety of quality measures such as adherence to renin-angiotensin system antagonists (RASAs). Adherence to RASA medications, defined as having a proportion of days covered (PDC) of at least 80%, has been improving for several years, suggesting that further investigation is needed to assess the appropriateness of the current 80% PDC threshold for medication adherence as an indicator of quality. The 80% PDC threshold has been found to be associated with improved health care resource utilization outcomes; however, little evidence exists to show that this threshold is optimal.

Objective: To evaluate the association between adherence to RASA medications and health care resource utilization outcomes within a Medicare Advantage population and to identify the optimal PDC threshold that maximizes economic and utilization benefits.

Methods: This retrospective cohort study used de-identified administrative claims data from the 2015 to 2018 in Optum's de-identified Clinformatics Data Mart Database. Inclusion in the study was based on measure specifications for the RASA adherence measure used in the Medicare Part D Star Ratings program. Adherence was assessed over a 1-year period, and health care utilization and medical costs were assessed in the subsequent year. Multivariable logistic regression models were used to assess the relationship between adherence and economic outcomes after accounting for hypothesized confounders.

Results: A total of 1,006,901 individuals were included in the study with an average PDC of 87.5% (SD = 17.8%). During the follow-up period, 12.1% of individuals experienced a hospitalization, 14.81% used an emergency department (ED), and 32.3% visited a non-ED outpatient facility. Each percentage point increase in PDC was significantly associated with decreased odds of hospitalization (odds ratio [OR] = 0.997; 95% CI = 0.997-0.997) and ED visit (OR = 0.997; 95% CI = 0.996-0.997), being in the top decile of payer medical costs (OR = 0.998; 95% CI = 0.997-0.998), and increased odds of outpatient visits (adjusted OR = 1.001; 95% CI = 1.001-1.002). Receiver operator characteristic curve analyses found the optimal PDC thresholds to be 91.5%, 90.7%, 90.7%, and 90.4% for hospitalization (area under the curve [AUC] = 0.527), ED visit (AUC = 0.534), outpatient visit (AUC = 0.501), and medical costs (AUC = 0.532), respectively.

Conclusions: This study demonstrated the importance of medication adherence for preventing undesirable outcomes, such as future hospitalizations, ED visits, and high medical costs, among individuals with hypertension enrolled in Medicare Advantage. The optimal threshold for PDC related to health care resource utilization outcomes was found to be greater than that used in the measure in CMS Star Ratings. Future research should examine the impact of changes in adherence thresholds for economic and clinical outcomes.

PubMed Disclaimer

Conflict of interest statement

Drs Campbell, Karmakar, and Black are employed by the study sponsor. Drs Bentley and Ramachandran have received grants from the Pharmacy Quality Alliance.

Figures

FIGURE 1
FIGURE 1
Study Design and Patient Timeline
See this image and copyright information in PMC

References

    1. MacLeod KE, Ye Z, Donald B, Wang G.. A literature review of productivity loss associated with hypertension in the United States. Popul Health Manag. 2022;25(3):297-308. doi:10.1089/pop.2021.0201 - PMC - PubMed
    1. Forouzanfar MH, Liu P, Roth GA, et al.. Global burden of hypertension and systolic blood pressure of at least 110 to 115 mm Hg, 1990-2015. JAMA. 2017;317(2):165-82. doi:10.1001/jama.2016.19043 - PubMed
    1. Centers for Disease Control and Prevention. About multiple cause of death, 1999-2020. Accessed May 31, 2023. https://wonder.cdc.gov/mcd-icd10.html
    1. Centers for Disease Control and Prevention. Estimated hypertension prevalence, treatment, and control among U.S. adults. Published May 12, 2023. Accessed May 31, 2023. https://millionhearts.hhs.gov/data-reports/hypertension-prevalence.html
    1. Farley TA, Dalal MA, Mostashari F, Frieden TR. Deaths preventable in the U.S. by improvements in use of clinical preventive services. Am J Prev Med. 2010;38(6):600-9. doi:10.1016/j.amepre.2010.02.016 - PubMed

Substances

LinkOut - more resources